Your Health, We Care
Release date: 2024-08-12 10:56:09 Recommended: 145
Pemigatinib is a targeted therapy drug developed by Incyte in the United States, mainly for the treatment of cholangiocarcinoma, especially in adult patients with previously treated, unresectable locally advanced, or metastatic cholangiocarcinoma.
One of the commonly used specifications is the 4.5mg*14 tablets produced by Lucius Pharmaceutical Co., Ltd. This specification is designed with the patient's medication needs and convenience in mind, making it easy to carry and adjust the dose according to the doctor's instructions.
In the market, the 4.5mg*14 tablets of Pemigatinib produced by Lucius Pharmaceutical Co., Ltd. are relatively reasonably priced, aiming to provide patients with high-quality treatment while minimizing their financial burden, with a retail price of about RMB 1,400 per box, which is competitive with similar drugs and makes this innovative treatment affordable for more patients.
The exact cause of cholangiocarcinoma is still unknown, but the medical community has revealed a range of risk factors.
Most patients with cholangiocarcinoma are over half a hundred years old; Specific pathological conditions, such as primary biliary cirrhosis and intrahepatic cholangitis, are also implicated, which may act as catalysts to accelerate the carcinogenesis of the bile ducts.
Environmental and occupational exposures are also considered to be potential sources of risk, and prolonged exposure to hazardous environments or high-risk occupations may silently increase the risk of cholangiocarcinoma. However, even in the absence of these clear risk factors, some patients may still experience the invasion of cholangiocarcinoma, highlighting the complexity and diversity of the causes of the disease.
In the early stages of cholangiocarcinoma, the symptoms are often subtle and difficult to detect, but as the disease quietly deteriorates, the patient will gradually show warning signs such as jaundice, vague pain in the right upper quadrant, unexplained weight loss, persistent fatigue and loss of appetite. The appearance of these symptoms is often a sign that the disease has entered the middle and advanced stages.
The key to the treatment of cholangiocarcinoma is early diagnosis and timely intervention, which can significantly improve the survival chances of patients. At present, the main treatment strategies for cholangiocarcinoma are surgery, chemotherapy, and radiotherapy. The purpose of surgery is to accurately remove the cancer and strive for a radical cure; Chemotherapy and radiotherapy, on the other hand, are adjuncts designed to destroy latent cancer cells or halt their expansion.
However, in view of the fact that cholangiocarcinoma is often hidden until an advanced stage, the overall prognosis is not optimistic, and there is a risk of recurrence even after surgery, which requires the joint efforts of patients and doctors to continue monitoring and active response.
【Warm tips】When patients buy generic drugs, they should choose formal channels to ensure the quality and safety of the drugs. Avoid purchasing counterfeit products from informal sources.
